These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 24364782)
1. Massive ascites in pulmonary arterial hypertension: caution with epoprostenol. Kataoka M; Yanagisawa R; Yoshino H; Satoh T Ann Am Thorac Soc; 2013 Dec; 10(6):726-7. PubMed ID: 24364782 [No Abstract] [Full Text] [Related]
2. Transition from Intravenous Epoprostenol to Treprostinil Due to Intolerable Side Effects in Patients With Pulmonary Arterial Hypertension. Kikuchi H; Goda A; Takeuchi K; Inami T; Kohno T; Soejima K; Satoh T Am J Cardiol; 2023 Nov; 206():31-34. PubMed ID: 37677880 [TBL] [Abstract][Full Text] [Related]
3. Infections by gram-negative bacilli in patients with pulmonary arterial hypertension treated with intravenous prostacyclin. Gómez Sánchez MA Arch Bronconeumol; 2013 Mar; 49(3):128-9. PubMed ID: 23127721 [No Abstract] [Full Text] [Related]
5. ACTH deficiency and PGI(2) therapy in chronic thromboembolic pulmonary hypertension. Ikari J; Tanabe N; Tatsuno I; Yamanaka M; Sakao S; Tada Y; Kurosu K; Kasahara Y; Takiguchi Y; Tatsumi K Int J Cardiol; 2011 Feb; 146(3):449-50. PubMed ID: 21093079 [No Abstract] [Full Text] [Related]
6. Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma. Farber HW; Graven KK; Kokolski G; Korn JH J Rheumatol; 1999 May; 26(5):1195-6. PubMed ID: 10332990 [TBL] [Abstract][Full Text] [Related]
7. Cutaneous findings in patients with pulmonary arterial hypertension receiving long-term epoprostenol therapy. Myers SA; Ahearn GS; Angelica Selim M; Tapson VF J Am Acad Dermatol; 2004 Jul; 51(1):98-102. PubMed ID: 15243533 [TBL] [Abstract][Full Text] [Related]
8. Oral prostacyclin therapy for pulmonary arterial hypertension: another step forward. Waxman AB Circulation; 2013 Feb; 127(5):563-5. PubMed ID: 23307828 [No Abstract] [Full Text] [Related]
9. Reply to letter to the editor "infections by gram-negative bacilli in patients with pulmonary arterial hypertension treated with intravenous prostacyclin". López-Medrano F; Fernández-Ruiz M; Ruiz-Cano MJ; Escribano P Arch Bronconeumol; 2013 May; 49(5):217-8. PubMed ID: 23218502 [No Abstract] [Full Text] [Related]
10. Ondansetron eliminates nausea and vomiting associated with prostacyclin in a patient awaiting lung transplantation. Lawhorn S; Lawhorn CD; Davison C J Heart Lung Transplant; 1997 Apr; 16(4):472-3. PubMed ID: 9154961 [No Abstract] [Full Text] [Related]
11. [Prostacyclin and iloprost in aerosol form in severe pulmonary hypertension]. Olschewski H; Walmrath D; Schermuly R; Ghofrani HA; Grimminger F; Seeger W Pneumologie; 1998 Jan; 52(1):3-7. PubMed ID: 9540363 [No Abstract] [Full Text] [Related]
12. [Therapy of severe pulmonary hypertension with prostacyclin and iloprost]. Matthes J; Mathen F; Herzig S; Wassermann K Dtsch Med Wochenschr; 2001 May; 126(21):631-7. PubMed ID: 11413752 [No Abstract] [Full Text] [Related]
13. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Humbert M; Barst RJ; Robbins IM; Channick RN; Galiè N; Boonstra A; Rubin LJ; Horn EM; Manes A; Simonneau G Eur Respir J; 2004 Sep; 24(3):353-9. PubMed ID: 15358690 [TBL] [Abstract][Full Text] [Related]
14. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477 [TBL] [Abstract][Full Text] [Related]